Strategic Update & Entitlement Offer Presentation
Released
Released
Announcement PDF
Creating tomorrow’s therapies
from today’s patient stories
(ASX:EMD)
Strategic Update & Rights Issue Launch
September 2023 | mwinlo@emyria.com
OUR MISSION
Set a new standard for global mental health care
by blending compassionate care, data insights
and pioneering therapies.
7 INVESTMENT HIGHLIGHTS for EMYRIA (ASX : EMD)
Australia is
leading the
charge globally
in new
treatments for
mental health
At the forefront
of psychedelic
assisted
treatment
Novel MDMA
products
Unparalleled
access to
patient data
Clinics
delivering
revenue
CBD “Side bets” Experienced
management
team
The TGA’s decision to
legalise psychedelics,
which came into
force in July 2023,
puts Emyria and
Australia potentially
years ahead of other
jurisdictions like the
US.
Emyria has the
infrastructure (clinics
and team) and
approved care
models needed to
provide psychedelic
treatments under
TGA rules.
Emyria has
partnered with UWA
to develop a number
of novel MDMA-like
treatments.
Through our clinics,
Emyria has access to
opt-in patient data
and uses a
state-of-the-art data
platform - Palantir
Foundry - to reveal
unique insights.
Emyria provides
wraparound,
multidisciplinary
mental health care
services to patients.
Emyria is developing
Ultra-Pure CBD for
the treatment for
anxiety symptoms
and pain.
We made $1.6M last
FY, targeting $5.7M
this FY.
We have secured a
commercial partner
and are working with
others, such as, the
National Institutes of
Health in the US to
advance the
program
A regulatory
environment that
advantages Emyria
Ready to be one of
the first ASX
companies
providing these
treatments
Strong IP covering
potentially unique
medicines
Data that informs
better care
practices and drug
development
opportunities
Revenues
subsidise R&D
CBD products in
clinical trials
The goal is to modify
MDMA and unlock
new therapeutics for
neuropsychiatric
disorders like
Parkinson’s disease.
Emyria’s Board and
Management are
highly qualified in
technology-backed
clinical services, data
and drug
development.
Global advisors to
support our global
ambitions
Emyria 2023
3
THE GLOBAL MENTAL HEALTH CHALLENGE | SEEKING NEW SOLUTIONS
Rising Demand,
Inadequate Solutions
The Promise of
Psychedelic-Assisted
Therapy
The Challenge of
Psychedelic-Assisted
Therapy
Psychedelic-assisted therapy is showing
promising results in large clinical trials. 2
Safe delivery of psychedelic-assisted therapy
demands cooperation between therapists and
psychiatrists, thoughtful preparation of the clinic
environment and careful diagnosis, screening,
expectation setting and monitoring with patients.
$225 Billion
US Spending (2019) 1
Despite large costs, a gaping need for affordable,
effective and durable treatments persists.
This is encouraging significant clinical
interest and investment, globally.
Very few clinical services are prepared for these
treatments, limiting patient access.
SOURCES:
1. https://www.behavr.com/mental-wellness
2. Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27, 1025–1033 (2021)
3. https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin
Emyria 2023
4
AUSTRALIA'S FRONTIER | EMBRACING DRUG-ASSISTED THERAPIES
Leading the Global
Charge
TGA's recent rescheduling 1 of MDMA-assisted therapy
(MDMA-AT) for PTSD & psilocybin-assisted therapy
(P-AT) for treatment resistant depression creates
immense potential for innovators in mental health.
Not Just Drugs,
But Holistic Care
Emyria’s Model is
Well Positioned
The future of mental healthcare will
intertwine new drugs with new care models.
“For approval to prescribe, psychiatrists will need to
demonstrate appropriate training,
patient selection, evidence-based treatment
protocols and patient monitoring.
With unique expertise in drug development
& care delivery, underpinned by data, Emyria
is uniquely prepared to lead this new frontier.
CARE DELIVERY
Further, ongoing psychotherapeutic support
remains an essential component of the
psychedelic treatment model.”
-RANZCP (College of Psychiatrists) 2
REAL WORLD
DATA
Australia's proactive stance on psychedelic therapies
places it at least a year ahead of the rest of the world.
SOURCES:
1. https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin
2. RANZCP has not provided its consent to be named or for the statement to be included in this Presentation
THERAPY DEVELOPMENT
EMYRIA’S UNIQUE BUSINESS MODEL | MERGING CARE DELIVERY & DRUG DEVELOPMENT
care DELIVERY
●
●
●
●
National clinics & telehealth
30 clinicians & specialists
14,000+ patients treated so far
Innovative care provision:
○
MDMA-AT
○
Cannabinoid medicines
real-world DATA
●
●
●
We track clinical outcomes
Palantir Foundry as core data
platform for analysis
Remote patient monitoring
Potential for sustainable service Revenues & Data
drug DEVELOPMENT
●
●
MDMA-inspired medicines
Ultra-Pure CBD medicines
Potential for Milestone &
License Revenues
Emyria 2023
6
CREATING & CAPTURING VALUE | OUR STRATEGY FOR GROWTH & IMPACT
(1) Solidify Multiple Potential
Revenue Streams Via:
(2) Sustainable National
and Global Growth Via:
DIRECT PATIENT TREATMENTS:
Provides potential to generate steady
revenues from patients and health payers.
We specialise in emerging treatments.
TECH-DRIVEN OPTIMISATION
Leveraging technology ensures efficient
operations, better patient outcomes, &
scalability.
STRATEGIC CLINICAL PARTNERS:
By licensing our methodologies we can
potentially unlock additional revenues and
foster innovation. 1
EXTENDING OUR FOOTPRINT:
With a robust model in place, we can
expand organically or via strategic
partnerships or acquisitions.
DRUG PROGRAM LICENSES:
As our drug development initiatives mature
and succeed, they may present revenue
opportunities through licensing and
partnerships.
1.
No licensing or partnership agreements have been entered as at the date of the presentation but it is a focus point of the Company in the near term to progress negotiations for such
agreements
Emyria 2023
7
OUR CURRENT FOCUS | COMPLEX MENTAL HEALTH
35% of Australian adults experienced at least 1 mental health challenge in the last 12 months 1
Anxiety disorders
(28%)
PTSD
(6%)
Amidst Australia's mental health
landscape, we're prioritising unmet
needs in anxiety disorders with
proprietary dose forms of
cannabinoids and MDMA-AT for
complex & chronic PTSD.
As PTSD shares substantial symptom
overlap with depression and chronic
pain, we believe our approach has the
potential to positively impact these
adjacent mental health conditions.
Affective disorders
(8%)
Substance abuse
(3%)
Given the recent TGA changes and
our multidisciplinary team, Emyria is
starting with MDMA-AT for PTSD.
SOURCES:
1. https://www.abs.gov.au/statistics/health/mental-health/national-study-mental-health-and-wellbeing/latest-release#key-statistics
Emyria 2023
8
A chronic, debilitating mental health disorder
that can occur following a traumatic event
WHAT IS POST-TRAUMATIC STRESS DISORDER (PTSD)? 1
Symptoms
Current
Treatments
Market for
MDMA-AT 3
Total Addressable Market (TAM)
In any 12 month period, PTSD affects 6% of
Australian adults
~1,000,000 (much greater globally)
Re-experiencing:
Intrusive memories, flashbacks, and
nightmares
Avoidance:
Evading reminders of the trauma and
feeling detached
Increased arousal:
Irritability, sleep issues, and being easily
startled
TREATMENT OPTIONS FOR PTSD
COUNSELLING &
PRESCRIPTION
PSYCHOTHERAPY
Mood & cognition:
Persistent negative emotions and
distorted blame
Physical symptoms:
Palpitations, sweating, and
gastrointestinal issues
Up to
EXPOSURE
GROUP
THERAPY
THERAPY
Re-imagining
events in a
safe
environment
50% treatment resistance
2
Serviceable Addressable Market (SAM)
50% of sufferers have treatment
chronic/severe PTSD; ~22% not suitable
Eligible for MDMA-AT ~400,000
Early Target Market
1-10% of patients suitable for MDMA-AT
in Western Australia:
~300 to 3,000 patients
At ~$30k/pt for three MDMA-AT sessions,
there exists an opportunity for transformative
healing for patients and a promising revenue
stream to support our growth
SOURCES:
1. Davis LL, Schein J, Cloutier M, et al. The economic burden of posttraumatic stress disorder in the United States from a societal perspective. J Clin Psychiatry. 2022;83(3):21m14116
2. Committee on the Assessment of Ongoing Efforts in the Treatment of Posttraumatic Stress Disorder; Board on the Health of Select Populations; Institute of Medicine. Washington (DC): National
Academies Press (US); 2014 Jun 17.
3. See workings on SLIDE 31
Emyria 2023
9
MDMA-ASSISTED THERAPY (MDMA-AT) SHOWING REMARKABLE PROMISE FOR PTSD 1
Improves symptoms
Improves function
Durable benefits
“
MDMA-AT significantly attenuated PTSD
symptomology, as shown by the change in CAPS-5 total
severity score from baseline to 18 weeks after baseline¹
MDMA-AT significantly reduced clinician-rated
functional impairment, implying an improved quality
of life, as shown by the change in Sheehan Disability
Scale score from baseline to 18 weeks after baseline¹
The majority of participants
reported lasting benefits at Long
Term Follow-Up, and over half
reported benefits continued to
grow, suggesting participants
were able to successfully
integrate therapeutic
experiences into their daily lives
to cultivate continued healing
and growth” 1
SOURCES:
1. Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27, 1025–1033 (2021)
Emyria 2023
10
HOW DOES MDMA-AT WORK?
MDMA
Clinical Effects of MDMA
MDMA is an “entactogen” - drugs
that produce feelings of emotional
communion, oneness, relatedness,
emotional openness & fear extinction.
MDMA (3,4-methylenedioxymethamphetamine or “ecstasy”)
Causes release of 3 neurotransmitters:
feelings of wellbeing
INCREASES
sociability & extroversion
interpersonal trust
Serotonin
contributes to mood,
prosocial effects
AN ALERT STATE OF
CONSCIOUSNESS
Dopamine
associated with reward,
euphoria
Noradrenaline
stimulant activity,
attention
DECREASES
feelings of fear &
defensiveness
Role in Therapy
MDMA is thought to assist patients access
traumatic memories without overwhelming
distress.
The improved feelings of trust and wellbeing
while under the influence of the medication can
support open communication and strengthen
the therapeutic alliance between patient and
therapist.
Reduced defensiveness is thought to facilitate
more honest introspection and acceptance of
therapeutic guidance.
Ultimately, these features are believed to improve
the efficacy of skilled psychotherapy.
Risks & Exclusions
Patients with cardiovascular disease or
psychotic disease are generally excluded from
therapy. The main side effects of therapy can
include anxiety, restlessness, fatigue,
jaw-clenching, headache and transient
increases in blood pressure - all of which are
closely monitored during therapy.
Emyria 2023
11
EMYRIA’S MDMA-AT MODEL
Ethics-Approved
Care Model 1
Anticipated Cost-Effective
Compared to Standard Care2
Who Might Pay For
MDMA-AT?
Health insurers and government
We will approach payers to offer our support in
the evaluation cost-effectiveness for these new
treatment approaches.
Fit-for-purpose clinical space
Trained multidisciplinary team
Stringent clinical governance & oversight
Two therapists for all sessions
GMP-grade medicine & tight supply chain
PRE-TREATMENT PERIOD
2-12 weeks
~$30k
3 CONSECUTIVE TREATMENT & INTEGRATION PERIODS
(12 weeks)
MDMA-AT anticipated to be cost effective especially
for severe PTSD over an 18 month time period. 2
FOLLOW-UP PERIOD
(12 months from last Treatment Session)
Avenceña et al noted that increased access to
MDMA-AT could save lives and improve the health of
patients with chronic and severe PTSD, while reducing
healthcare costs. 3
Individual patients - patients will not be
expected to pay while participants in clinical
trials, however, once Authorised Prescriber
status has been obtained there is the
possibility to offer access to patients able to
pay out-of-pocket
SOURCES:
1. See ASX release 08 June 2023
2. Cost estimates from internal evaluation. Majority of costs related to Standard of Care related to in-patient treatment costs. Majority of costs related to MDMA-AT related to length of therapist engagement
3. See Avanceña, A.L.V., et al. The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study. Clin Drug Investig 42, 243–252 (2022) AND
Emyria 2023
12
OUR TEAM’S ADVANTAGES | LEADERS IN CARE, DATA and DRUG DEVELOPMENT
Innovative Care
Delivery
Data, Research &
Technology
Global Drug
Development Success
Our team has experience across clinical
care, consulting, and academia. With
backgrounds ranging from specialist
medical practitioners with esteemed
roles in primary health care and medical
councils, our team understands the
challenges and intricacies of sustainable
healthcare delivery.
With experience at from Silicon Valley
tech giants to innovative healthcare tech
startups, our team understands the world
of complex data integration and analysis.
With experience advising the FDA on
tech initiatives and leadership roles in
healthcare data firms, we understand the
potential for modern tech and data to
revolutionise mental health care.
Our team has experience across the vast
spectrum of the drug development
lifecycle. With involvement in numerous
clinical trials, major regulatory approvals
across continents, and leadership in
global biotech firms, we have the breadth
and depth of knowledge to navigate the
intricate pathways of drug innovation.
Emyria 2023
13
OUR BOARD
CHAIRMAN
NE-DIRECTOR
E-DIRECTOR
MANAGING DIRECTOR
NE-DIRECTOR
MEDICAL DIRECTOR
Dr Stewart Washer
PhD (Microbiology)
Serial entrepreneur
Multiple ASX listings
Prof Sir John Tooke
FRCP, FMedSci
Clinician-researcher
Expert in learning health
systems
Dr Karen Smith
MD, PhD, MBA, LLM
US-based biopharma
executive. Multiple FDA
approvals
Dr Michael Winlo
MBBS(Hons), MBA
Entrepreneur, big data,
clinical trials and
drug development
Dr Mohit Kaushal
Technology enabled
clinical services,
strategy and
investment
C/Prof Alistair Vickery
MBBS, FRACGP, FCHSM
Medical Director
Epidemiological researcher
Prof Matt Piggott
BSc, PhD (Chemistry)
Specialist in amphetamine
chemistry and novel
drug design
Dr David Gunn
MBBS, FRACGP
Cannabinoid expert
Substance abuse &
mental health
treatment
CLINICAL & SCIENTIFIC LEADERSHIP
Claire Kullak
BSc (Nursing)
Trauma-specialist and
nationally recognised
trainer
Dr Jon Laugharne
MBBS, FRCP (UK),
FRANZCP
Consultant psychiatrist &
therapist
Dr Jenny Morgan
MBBS, FRANZCA
Consultant pain specialist
Dr Jeremy Tannenbaum
BSc, MBBS (Hons), FRANZCP
Consultant Pain Specialist
Consultant Psychiatrist
Emyria 2023
14
PROVEN MOMENTUM | TRACTION TO DATE
Key Milestones
Achieved
MDMA-assisted therapy (MDMA-AT)
Ethics-approved protocol, training
completed & drug supply secured 1
>150 Novel MDMA analogues
Created and screened large library of
unique MDMA-like compounds 2
Robust Patient
Outcomes
14,000
Patients treated through our clinical
services network
30% reduction in opioids
After 6 months care at Emerald Clinics 5
3 proprietary dose forms of CBD
In preclinical and clinical trials 3
Commercial partner
Secured Aspen Pharmacare for sales and
distribution of EMD-RX5 pending
successful registration with the TGA 4
SOURCES:
1. See ASX release 08 June 2023
2. See ASX release 20 March 2023
3. See ASX release 04 April 2023
4. See ASX release 04 April 2023
Strategic Growth
Initiatives
4 years of symptom improvement
Across anxiety, depression, stress & sleep 6
SOURCES:
5. See ASX release 07 June 2021
6. Vickery AW, et al (2022) A large Australian longitudinal cohort
registry demonstrates sustained safety and efficacy of oral
medicinal cannabis for at least two years. PLOS ONE 17(11): e0272241
Acquisition of Australia’s leading,
multidisciplinary psychological trauma
treatment centre 7
Member the Foundry For Builders Program
providing access to the world’s most
advanced data platforms 8
Future:
Launch new care programs
Advance drug development programs
Clinical partnerships
SOURCES:
7. See ASX release 03 July 2023
8. See ASX release 07 October 2021
Emyria 2023
15
OUR ROADMAP
#
PROGRAM
MILESTONE 1
MILESTONE 2
MILESTONE 3
OTHERS
1
Deliver MDMA-AT
Begin treatment on
first patient (MDMA)
Emyria psychiatrists
obtain Authorised
Prescriber status
Complete patient
recruitment for
Phase 2b trial
(MDMA)
Complete Phase
2b trial for
MDMA
2
Develop Novel MDMA Treatments
Animal study results
for fast-acting MDMA
analogue
Animal study results
for Parkinson’s
MDMA analogue
Identify lead drug
candidates for
Phase 1 trial
Expand to Psilocybin & Ketamine Therapies
Approval for ketamine
assisted therapy
protocol
Begin treatment on
first patient
(ketamine)
Secure key
approvals for
psilocybin use
CBD "Side Bet" Clinical Trials
Recommence Phase 3
trial of low-dose CBD
for stress & anxiety
Begin Phase 1 trial of
high-potency CBD
treatments
Results of Phase 1
trial of
high-potency
CBD treatments
Scale Clinical Health Services & Engage Payers
Secure a major payer
partnership
Licence a care
model to a clinical
partner
Open a new clinic
or form new
clinical
partnership
Expand Intellectual Property & Build Partnerships
Receive Clear Search
Report from
international patent
examiner
Secure granted
patents in national
phase
File new patent
family
provisionals
3
4
5
6
Begin
treatment on
first patient
(psilocybin)
Updated
commercial
license with
UWA
OUR CORPORATE STRUCTURE
KEY METRICS
VALUE
Market Capitalisation
~A$31M
Last reported cash
(at 30 Jun 2023)
A$2.73M
+ $2m Placement (Sep)
+ $3.1m Rights Issue (Oct)
Tenmile
7.8%
Other Holdings
Directors
27%
Top 50
67.2%
Emyria 2023
17
ENTITLEMENT OFFER TO RAISE $3.1m
Emyria 2023
18
ENTITLEMENT OFFER | OVERVIEW
Emyria (EMD) is launching a Entitlement Offer (“Offer”) to provide existing shareholders the
opportunity to invest in advancing the next phases of our highly promising clinical programs.
Offer is expected to raise
$3.1m (before costs) to fund Emyria’s
leading programs.
For every 7.5 shares held by the Record Date,
shareholders will be eligible to apply for 1
shared priced at $0.075.
Under the Offer, all shareholders holding
Emyria shares by the Record Date (Wed,
Sep 13th) will be eligible to participate.
New shares issues will rank pari passu with
existing shares from their date of issue.
Full Details and Prospectus available
6 September 2023.
In addition, each successful applicant will be
entitled to 1 free attaching, unlisted option
for every 2 shares purchased under the
Offer.
Emyria 2023
19
ENTITLEMENT OFFER | USE OF FUNDS
$3.1m
PROPOSED EXPENDITURE
CARE DELIVERY
Finalise Pax Acquisition
$500,000
Authorised prescriber launch
$375,000
Service expansion (ketamine)
$775,000
DRUG DEVELOPMENT
* Emyria retains the discretion to alter any or all of these dates
CBD drug optimisation
$350,000
MDMA-analogues 1 lead series to animal studies
$793,300
DATA
$250,000
OFFER FEES
$56,700
Emyria 2023
20
ENTITLEMENT OFFER | INDICATIVE TIMETABLE
Event
Date (2023)
Lodgement of Entitlement Offer Prospectus with ASIC
5 September
Announcement of Entitlement Offer Prospectus and investor presentation on ASX
6 September
Entitlement Offer “Ex” date
Expected date for quotation of new shares issued under the Placement
12 September
Record Date to identify security holders entitled to participate in the Entitlement Offer
13 September
Entitlement Offer Prospectus and personalised entitlement and acceptance forms made
available to persons entitled and announcement that this has occurred
Entitlement Offer opening date
18 September
Entitlement Offer closes at 5:00pm (AWST)
28 September
Announcement of the results of the Entitlement Offer
Appendix 2A and 3G for Entitlement Offer
5 October
* Emyria retains the discretion to alter any or all of these dates
Emyria 2023
21
ENTITLEMENT OFFER (RIGHTS ISSUE) | WEBSITE EXPLAINING THE OFFER
OFFER.EMYRIA.COM
Emyria 2023
22
ENTITLEMENT OFFER | DISCLAIMER
In accordance with section 734(6) of the Corporations Act, the Company notes that:
●
the Entitlement Offer will be undertaken pursuant to a disclosure document issued by the
Company in accordance with section 713 of the Corporations Act (the Prospectus);
●
the Prospectus is available on the Company’s website (www.emyria.com) and the ASX Market
Announcements Platform under the Company’s ASX code “EMD”;
●
participants in the Entitlement Offer should consider the Prospectus in full before deciding to
participate and acquire securities under the Entitlement Offer; and
●
any participants in the Entitlement Offer will be required to complete the application form that
will be in or will accompany the Prospectus.
Emyria 2023
23
CONTACT INFORMATION
Michael Winlo
Investors
Media
General
INVESTOR HUB:
https://investorhub.emyria.com/
mwinlo@emyria.com
investors@emyria.com
media@emyria.com
info@emyria.com
APPENDIX:
Emyria 2023
25
DISCLAIMER to presentation
This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or
recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only
and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the
information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and
needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates,
opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or
implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation.
Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To
the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including
without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything
contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown
risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The
distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe
any such restrictions.
This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of
Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's
current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends,"
"plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such
statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of
building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties
and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in
the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the
view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are
made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated
events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Presentation release authorised by Michael Winlo, CEO and Managing Director
Emyria 2023
26
EMYRIA CLINICS | OUR EXPANDING MENTAL HEALTH FOOTPRINT
We offer a suite of solutions & ongoing support, not just a single service
A data-centric clinic working with newly rescheduled treatments like THC
& CBD. We monitor & care for patients when “nothing else has worked”
Australia’s leading, multidisciplinary treatment centre for psychological trauma
Emerald Cli
●
GP-led clinical service
● ~10,000+ patients
● 40+ clinical conditions
● Cannabinoid-based medicine
specialists
● World’s largest data registry on
cannabinoid-based therapies and
outcomes 1
● Leveraging
Foundry 2
SOURCES:
1. Arkell TR, et al. Assessment of Medical Cannabis and Health-Related Quality of Life. JAMA Netw Open. 2023;6(5):e2312522. doi:10.1001/jamanetworkopen.2023.12522
2. See ASX 22 Oct 2021
●
Psychiatrist-led service
for complex trauma care 1
● Diverse service offering
● 19 clinicians: psychiatrists,
mental health nurses,
psychologists, counsellors, OTs
& social workers, physical
therapists
● Ethics-approved psychedelic assisted therapy model 2
Emyria 2023
27
EMYRIA CLINICS | A PERSONALISED PATH TO MENTAL WELLNESS
We offer wraparound care before, during and after treatment
ACTIVE ASSESSMENT, DATA
COLLECTION & REVIEW
Neuropsychiatric disorders share an overlapping imprint of poor body health 1 which is why Emyria’s care models prioritise both physical and mental well-being.
By providing comprehensive care we can achieve and measure exceptional health outcomes as well as develop new therapies and approaches, including our own.
EVIDENCE-BASED CARE
Rapid intake
and assessment
Evidence-based care led by
psychiatrists & managed by GPs and
specially-trained therapists
EMERGING TREATMENTS
TMS and / or
Cannabinoid Therapy
SOURCE:
1. Tian YE, et al Evaluation of Brain-Body Health in Individuals With Common Neuropsychiatric Disorders. JAMA Psychiatry. 2023 Apr 26
CLINICAL TRIALS
Psychedelic-assisted
Therapy
Experimental
Treatments
Emyria 2023
28
EMYRIA CLINICS | MULTIDISCIPLINARY MODEL
EMYRIA ADVANTAGES
SERVICE MODEL
KEY STRENGTHS
KEY LIMITATIONS
GP Clinics
Accessible,
generalised care
Limited support;
not specialised
✓
Provides specialised care with
robust support
Specialists
High-level,
specialised care
Often do not address physical
health
✓
Offers multidisciplinary care covering
mental & physical health
“Single service”
clinics
(eg. “Ketamine
Clinics”)
Specialised service
Referral risk for clinicians.
“Where do my patients go if
treatment fails?”
✓
Offers a suite of services before, during
after care
Academic &
Research Centers
Cutting-edge research
and treatments
Not focused on scalable, cost
effective delivery
✓
Combines innovative approaches that translate
to the community cost effectively
✓
EMYRIA MODEL
Multidisciplinary,
data-driven,
revenue-generating
The infrastructure and team to deliver
new and emerging treatments while
collecting data to support ongoing
innovation and development
---
&
Emyria 2023
29
MDMA-AT EFFECTS On Alcohol and Substance Disorder (“ASUD”) & Suicidality
MDMA-AT may lead to subclinical
improvements in alcohol use
MDMA-AT does not increase risk of illicit
drug use
Compared to Placebo+therapy,
MDMA-AT was associated with a
significantly greater reduction in mean
AUDIT change scores as compared to
placebo.¹,²
Changes in DUDIT scores were not
significantly different between treatment
groups.¹
Sources:
1.
2.
MDMA-AT may reduce the risk of suicidality
Serious suicidal ideation (a score of 4 or 5 on the C-SSRS) was
minimal during the MAPP1 study and occurred almost entirely
in the placebo arm.¹
Nicholas CR, Wang JB, Coker A, Mitchell JM, Klaire SS, Yazar-Klosinski B, Emerson A, Brown RT, Doblin R. The effects of MDMA-assisted therapy on alcohol and
substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 2022 Apr 1;233:109356. doi: 10.1016/j.drugalcdep.2022.109356. Epub 2022 Feb 11. PMID:
35286849; PMCID: PMC9750500.
Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27,
1025–1033 (2021). https://doi.org/10.1038/s41591-021-01336-3
Emyria 2023
30
EPIDEMIOLOGY OF POST-TRAUMATIC STRESS DISORDER 1
USA
AUSTRALIA
WESTERN
AUSTRALIA
Adults
aged > 18
(millions)
% with
current
PTSD
Adults
with
PTSD
% with
chronic
and
severe
Adult PTSD
cases that
a
Share your feedback
Discover